CN1845907B - 胍衍生物 - Google Patents

胍衍生物 Download PDF

Info

Publication number
CN1845907B
CN1845907B CN2004800253298A CN200480025329A CN1845907B CN 1845907 B CN1845907 B CN 1845907B CN 2004800253298 A CN2004800253298 A CN 2004800253298A CN 200480025329 A CN200480025329 A CN 200480025329A CN 1845907 B CN1845907 B CN 1845907B
Authority
CN
China
Prior art keywords
guanidine
tetrahydro
rac
methyl
quinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800253298A
Other languages
English (en)
Chinese (zh)
Other versions
CN1845907A (zh
Inventor
安雅·费克尔
海茵策·弗雷茨
库尔特·希尔珀特
弗尔克尔·贝吕
托马斯·吉勒
奥利维尔·瓦尔登艾尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN1845907A publication Critical patent/CN1845907A/zh
Application granted granted Critical
Publication of CN1845907B publication Critical patent/CN1845907B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
CN2004800253298A 2003-09-05 2004-09-03 胍衍生物 Expired - Fee Related CN1845907B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH1526/03 2003-09-05
CH15262003 2003-09-05
PCT/CH2004/000556 WO2005023781A1 (de) 2003-09-05 2004-09-03 Guanidinderivate

Publications (2)

Publication Number Publication Date
CN1845907A CN1845907A (zh) 2006-10-11
CN1845907B true CN1845907B (zh) 2010-07-28

Family

ID=34230846

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800253298A Expired - Fee Related CN1845907B (zh) 2003-09-05 2004-09-03 胍衍生物

Country Status (16)

Country Link
US (1) US7544691B2 (enExample)
EP (1) EP1663993B1 (enExample)
JP (1) JP2007504176A (enExample)
KR (1) KR20060064065A (enExample)
CN (1) CN1845907B (enExample)
AT (1) ATE388943T1 (enExample)
AU (1) AU2004270304A1 (enExample)
BR (1) BRPI0414103A (enExample)
CA (1) CA2536927A1 (enExample)
DE (1) DE502004006515D1 (enExample)
ES (1) ES2300807T3 (enExample)
IL (1) IL173853A0 (enExample)
NO (1) NO20061531L (enExample)
PL (1) PL1663993T3 (enExample)
RU (1) RU2006110738A (enExample)
WO (1) WO2005023781A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
ATE359075T1 (de) 2002-12-20 2007-05-15 Niconovum Ab Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
KR101885503B1 (ko) * 2009-12-24 2018-08-07 사우디 아람코 테크놀로지스 컴퍼니 폴리사이클릭 구아니딘 화합물의 합성방법
EP3018125B1 (en) 2013-07-03 2020-08-05 Shin Nippon Biomedical Laboratories, Ltd. Novel compound, organic cation transporter 3 detection agent, and organic cation transporter 3 activity inhibitor
MX2019008078A (es) 2017-02-14 2019-11-05 Res Triangle Inst Moduladores de receptores neuropeptido basados en prolina.
CN108159032A (zh) * 2018-01-24 2018-06-15 昆明理工大学 二甲双胍在制备预防和/或治疗阿片类毒品成瘾药物中的应用和药物及制备方法
CN108159031A (zh) * 2018-01-24 2018-06-15 昆明理工大学 二甲双胍在制备预防和/或治疗苯丙胺类毒品成瘾药物中的应用和药物及制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003026667A1 (en) * 2001-09-24 2003-04-03 Synaptic Pharmaceutical Corporation Quinazolino- and quinolino- guanidines as ligands for the neurop eptide ff (npff) receptors
US20030139431A1 (en) * 2001-09-24 2003-07-24 Kawakami Joel K. Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3505327A (en) 1967-08-07 1970-04-07 American Cyanamid Co Tetrahydroquinoxalinyl phosphates or thiophosphates
BE795257A (fr) 1972-02-10 1973-08-09 Thomae Gmbh Dr K Nouveaux oxazols
DE3334455A1 (de) * 1983-03-04 1984-09-06 Bayer Ag, 5090 Leverkusen Guanidin - derivate
WO2003026657A1 (en) * 2001-09-24 2003-04-03 Synaptic Pharmaceutical Corporation Compounds for the treatment of pain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003026667A1 (en) * 2001-09-24 2003-04-03 Synaptic Pharmaceutical Corporation Quinazolino- and quinolino- guanidines as ligands for the neurop eptide ff (npff) receptors
US20030139431A1 (en) * 2001-09-24 2003-07-24 Kawakami Joel K. Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
说明书全文.

Also Published As

Publication number Publication date
EP1663993A1 (de) 2006-06-07
US7544691B2 (en) 2009-06-09
BRPI0414103A (pt) 2006-10-31
KR20060064065A (ko) 2006-06-12
DE502004006515D1 (en) 2008-04-24
AU2004270304A1 (en) 2005-03-17
NO20061531L (no) 2006-04-04
EP1663993B1 (de) 2008-03-12
IL173853A0 (en) 2006-07-05
PL1663993T3 (pl) 2008-08-29
US20070123510A1 (en) 2007-05-31
WO2005023781A1 (de) 2005-03-17
RU2006110738A (ru) 2007-12-10
CN1845907A (zh) 2006-10-11
JP2007504176A (ja) 2007-03-01
CA2536927A1 (en) 2005-03-17
ATE388943T1 (de) 2008-03-15
ES2300807T3 (es) 2008-06-16

Similar Documents

Publication Publication Date Title
TWI247745B (en) Amide derivatives, process for preparing same and pharmaceutical composition comprising same
US8026233B2 (en) P38 inhibitors and methods of use thereof
CN100355758C (zh) 胍衍生物及其作为神经肽ff受体拮抗剂的用途
WO2022261210A1 (en) Kras modulators and uses thereof
TW201010690A (en) Organic compounds
JP2003505384A (ja) ブラジキニンｂ１受容体アンタゴニスト
TWI671291B (zh) N-[2-(3-羥基-3-甲基丁基)-6-(2-羥基丙烷-2-基)-2h-吲唑-5-基]-6-(三氟甲基)吡啶-2-甲醯胺之結晶型
JP2002539141A (ja) 成長ホルモン分泌促進物質として有用なヘテロ環芳香族化合物
KR20180137497A (ko) N-｛6-(2-히드록시프로판-2-일)-2-[2-(메틸술포닐)에틸]-2h-인다졸-5-일｝-6-(트리플루오로메틸)피리딘-2-카르복스아미드의 다형체 형태
JP2002534512A (ja) 非ペプチドｇｌｐ−１アゴニスト
SG186228A1 (en) Urea derivatives and their therapeutic use in the treatment of, inter alia, diseases of the respiratory tract
CA3033913A1 (en) Heterocyclic apelin receptor (apj) agonists and uses thereof
CN1845907B (zh) 胍衍生物
AU2006237365B2 (en) 2,3 substituted pyrazine sulfonamides as inhibitors of CRTH2
US7645885B2 (en) Non-steroidal antiandrogens
JP2003513075A (ja) 複合５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体活性を有するイソキノリンおよびキナゾリン誘導体
CN101027054A (zh) Hsp90抑制剂
WO2015110077A1 (zh) 化合物A单苯甲酸盐的晶型α及其制备方法和含有该晶型的药物组合物
RS65711B1 (sr) Derivati sulfonilureje i njihova upotreba
TW201305130A (zh) 突變雄激素受體拮抗藥
CN107849018A (zh) 哌嗪衍生物
JP2002510625A (ja) Ｍｒｐ１の阻害方法
JPH0649034A (ja) プロペノイル−イミダゾール誘導体
JP2010529093A (ja) １−ベンジルピラゾール誘導体、その調製方法および治療的使用
TW201636352A (zh) 二環式吡啶化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100728

Termination date: 20120903